Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sugen (SUGN) -- Ignore unavailable to you. Want to Upgrade?

To: gao seng who wrote (520)	8/8/1999 8:48:00 PM
From: gao seng	Read Replies (1) \| Respond to of 550

Yes, I haven't given up on my research. Radiation seems to be conducive to metastases. This is not radiation bashing, but a clue in the race to find a cure for cancer. This data assumes the mass is not invasive, but there is really no way of knowing for certain. Outcome after local recurrence for patients with ductal carcinoma in situ (DCIS) of the breast. MJ Silverstein, M Lagios, JR Waisman, PH Craig, BS Lewinsky, P Gamagami, JA Jensen, A Barth. The Breast Center, Van Nuys, Ca., St. Marys Hospital, San Francisco, CA, Institute of Medical Oncology, University of Bern, Switzerland. Local recurrence after treatment for DCIS is demoralizing and, if invasive, a threat to life. We present data on 651 nonrandomized patients with a total of 68 recurrences, 32 of which (47%) were invasive. All survival data is 10-year actuarial (Kaplan-Meier). Mastectomy Excision +Radiation ExcisionOnly Number of patients (n = 651) 233 199 219 Total recurrences (n = 68) 2 32 34 Invasive recurrences (n = 32) 2 16 14 Distant metastases (n = 7) 2 4 1 Breast cancer deaths 0 3 0 Average DCIS size (mm) 40 18 14 Average followup (months) 82 91 70 Local disease-free survival 99 % 79 % 75 % Distant disease-free survival 99 % 97 % 99 % Breast cancer specific survival 100 % 98 % 100 % Overall Survival 90 % 87 % 89 % For the 68 patients who recurred locally, the 10-yr breast cancer specific and distant disease-free survivals were 94% and 80%, respectively. If only the 32 invasive recurrences are considered as events, the 10-yr breast cancer specific and distant disease-free survivals were 87% and 70%, respectively. These results indicate that most patients with local recurrences can be salvaged. For the small subgroup of patients who recur with invasive breast cancer, there is a 13% risk of death from metastatic disease within 10 years of local recurrence, a mortality rate similar to patients with T1a or T1b node negative primary breast carcinoma. asco.org